Seeking Alpha
29 Oct 2026, 13:50 UTC · 1h ago
Merck: A Strong Quarter, But It's Time To Take A Step Back
Impact · against what's priced in
Merck's Q3 beat is largely a confirmation of existing expectations regarding Keytruda's stability and the successful launch of new products. While the results are strong, they do not provide the structural catalyst needed to bridge the gap to the high-growth revenue CAGR the market currently declines to price in.
- MRK+0.05
Already priced in
- The price assumes
A steady continuation of Keytruda's current revenue
Keytruda's 5.6% YoY growth to $8.1 billion confirms the steady revenue continuation the market already assumes for the core pharmaceutical segment.
What MRK's price assumes · Sep 11
